ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB, Matching Placebo for TAK-279 Dose A clinical trials

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

This study is looking into a new medicine, Zasocitinib, for people with psoriatic arthritis. It's checking its long-term safety and how well it helps their symptoms. Participants will either get Zasocitinib or a dummy medicine.